Pre-Commercial Biotech Stocks Starting to Gain Favor. Big Tech Rotation Around the Corner?

August's VIX Wild Ride - A Trading Blip and Apparently Nothing More

August M&A Activity and Details

Biotech Markets Pricing in Rate Cuts as Index Stays Above 50-Day Average.

August 2024 Follow-Up with the Doctor

Record Low Volumes but Biotech Catching a Tailwind with Expectations of Rate Cuts

Low Trading Volume Reflects Wait and See Approach to Rates, Market Volatility

Biotech Capital Markets Highlights: Transactions 2X Over 2023

Government Announces Drug Price Controls

Earnings Season Continues with Beats. Market Poised for a Breakout but Appears Waiting on Rates

Biotech Stays Above 50-Day Moving Average and Crown Therapeutics Acquires Revance for $924M

Diving Into the Mortgage and Housing Market - Prices Remain High, Inventory Low, But the Future of Rates Has Investors, Borrowers, and Owners Engaged

A Look at Biotech Earnings Beats and Misses - Overall a Solid Quarter

The 10-year Yield Falls with S&P Biotech Index - Trends Breaking and Sector Optimistic

July 2024 Follow-Up with the Doctor

Collegium Acquires Ironshore Therapeutics for $525M and Big Pharma Rallies on Strong Earnings and IRA Policy Impact

There Is Still No Market Volatility! One 2% Up Day and Zero -2% Down Days in Almost a Year

Breaking Down of Momentum as a Leading Performance Metric Continues to Influence Biotech Sector